logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Deep Vein Thrombosis

    FiltersReset Filters
    10 results

    • dabigatran

      (DABIGATRAN ETEXILATE)
      AvKARE
      Usage: Dabigatran etexilate is indicated for reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism, preventing recurrence of these conditions, and for prophylaxis after hip replacement surgery in adult patients.

    • dabigatran etexilate

      (Dabigatran Etexilate)
      Alembic Pharmaceuticals Limited
      Usage: Dabigatran etexilate is indicated for reducing the risk of stroke and systemic embolism in non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism after parenteral anticoagulant use, preventing recurrence of these conditions, and providing prophylaxis following hip replacement surgery in adults.

    • eliquis

      (apixaban)
      E.R. Squibb & Sons, L.L.C.
      Usage: ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, as well as for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It also reduces the risk of recurrence of DVT and PE post-therapy.

    • enoxaparin sodium

      (Enoxaparin Sodium)
      Meitheal Pharmaceuticals Inc.
      Usage: Enoxaparin Sodium Injection is indicated for the prophylaxis and treatment of deep vein thrombosis (DVT), including for patients undergoing specific surgeries or with restricted mobility. It also prevents ischemic complications in unstable angina and treats acute ST-segment elevation myocardial infarction (STEMI) when used with aspirin.

    • enoxaparin sodium

      (Enoxaparin Sodium)
      Meitheal Pharmaceuticals Inc.
      Usage: Enoxaparin Sodium Injection is indicated for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism, prevention of ischemic complications in unstable angina and non-Q-wave myocardial infarction, and treatment of acute ST-segment elevation myocardial infarction (STEMI) when used with aspirin.

    • enoxaparin sodium

      (Enoxaparin sodium)
      Amphastar Pharmaceuticals, Inc.
      Usage: Enoxaparin Sodium Injection is indicated for the prophylaxis and treatment of deep vein thrombosis (DVT), including acute cases. It also prevents ischemic complications in unstable angina and non-Q-wave myocardial infarction, and treats acute ST-segment elevation myocardial infarction (STEMI) when used with aspirin.

    • heparin sodium

      (HEPARIN SODIUM)
      Fresenius Kabi USA, LLC
      Usage: Heparin Sodium Injection is indicated for the prophylaxis and treatment of venous thrombosis and pulmonary embolism, prevention of postoperative venous thromboembolism, atrial fibrillation with embolization, consumptive coagulopathies, and anticoagulant use in surgeries and procedures like blood transfusions and dialysis.

    • pradaxa

      (dabigatran etexilate mesylate)
      Boehringer Ingelheim Pharmaceuticals Inc.
      Usage: PRADAXA Capsules are indicated for reducing the risk of stroke and systemic embolism in adults with non-valvular atrial fibrillation, treating deep venous thrombosis and pulmonary embolism in adults, prophylaxis post-hip replacement surgery, and treating and preventing venous thromboembolic events in pediatric patients aged 8 to less than 18 years.

    • savaysa

      (EDOXABAN TOSYLATE)
      Daiichi Sankyo Inc.
      Usage: SAVAYSA is indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for treating deep vein thrombosis and pulmonary embolism after initial therapy with a parenteral anticoagulant. It should not be used in patients with CrCL > 95 mL/min.

    • xarelto

      (rivaroxaban)
      Janssen Pharmaceuticals, Inc.
      Usage: XARELTO is indicated for reducing the risk of stroke in nonvalvular atrial fibrillation, treating deep vein thrombosis (DVT) and pulmonary embolism (PE), preventing DVT after hip or knee replacement, and reducing major cardiovascular events in coronary artery disease. It's also used in pediatric patients for VTE treatment and prevention.